Drug intelligence / Profile preview

darolutamide + EBRT

Development stage: Unknown
Lead developer: Bayer
Modality: Small Molecules
Administration: Oral

Overview

Darolutamide + EBRT is an investigational combination regimen consisting of the androgen receptor antagonist darolutamide and external beam radiation therapy (EBRT). This regimen is being evaluated as an alternative to standard androgen deprivation therapy (ADT) plus EBRT for patients with unfavorable intermediate-risk prostate cancer. Darolutamide is a non-steroidal androgen receptor targeting agent (ARTA) characterized by low blood-brain barrier penetration and a favorable drug-drug interaction profile, which may reduce side effects like fatigue and cognitive impairment compared to traditional ADT. The combination is currently being studied in the Phase II DARIUS trial (NCT05346848) sponsored by Institut Bergonié.

Brand names: Nubeqa
Other names: darolutamide plus external beam radiation therapy

Targets

OATP1B1 (Organic anion transporting polypeptide 1B1)SLCO1B3 (Organic anion transporting polypeptide 1B3)ABCG2 (Breast cancer resistance protein)AR (Adrenergic receptors)

Beyond the preview

Go deeper on darolutamide + EBRT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on darolutamide + EBRT.

Explore the full profile